Pfizer Slams Appeal In Off-Label FCA Case In 1st Circ.
Two former sales reps failed to present evidence Pfizer used kickbacks to push off-label uses of an antipsychotic drug despite having ample opportunity to present their case, the pharmaceutical company said...To view the full article, register now.
Already a subscriber? Click here to view full article